Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 16/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | F9 | P00740 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19343473 | 0.92 | PHGDH (0.55) | PHGDHSLC6A9 | |
| SCHEMBL20768424 | 0.90 | PHGDH (0.50) | PHGDHSLC6A9F9MEN1NPC1 | |
| SCHEMBL20793599 | 0.90 | PHGDH (0.46) | PHGDH | |
| SCHEMBL19343488 | 0.90 | PHGDH (0.51) | PHGDHSLC6A9F9MEN1NPC1 | |
| SCHEMBL20768453 | 0.87 | PHGDH (0.48) | PHGDHSLC6A9F9MEN1NPC1 | |
| SCHEMBL20768409 | 0.85 | PHGDH (0.53) | PHGDH | |
| SCHEMBL20768402 | 0.83 | PHGDH (0.59) | PHGDHSLC6A9F9 | |
| SCHEMBL19343244 | 0.82 | PHGDH (0.55) | PHGDHF9POLB | |
| SCHEMBL23851712 | 0.82 | PHGDH (0.50) | PHGDHSLC6A9F9 | |
| SCHEMBL26373357 | 0.81 | PHGDH (0.56) | PHGDHSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884939-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3884939-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | Raze Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3426243-B1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885SLC6A9 1886/4885F9 4038/4885 |
| US-20230009122-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885SLC6A9 1886/4885F9 4038/4885 |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885SLC6A9 1886/4885F9 4038/4885 |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | PHGDH 1/4885SLC6A9 1886/4885F9 4038/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | PHGDH 1/4885SLC6A9 1886/4885F9 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.